Immupharma Plc (LON:IMM) Chairman Tim McCarthy talks to DirectorsTalk about the completion of the Lupuzor™ pivotal phase III study and an initiation of a follow up study. Tim explains the
he Times Apple gives British staff bonus from U.S. tax cut: Apple is to hand $2,500 bonuses to as many as 12,000 employees in the U.K. and Ireland as it
ImmuPharma PLC (LON:IMM), the specialist drug discovery and development company, has today confirmed that the ongoing 52-week, randomised, double-blinded, Phase III clinical trial of Lupuzor™, its lead programme for the
Deltex Medical Group plc (LON:DEMG), the global leader in Oesophageal Doppler Monitoring (“ODM”), has today announced the addition of a major new hospital in the USA. The hospital is a University
Deltex Medical Group plc (LON:DEMG), the global leader in Oesophageal Doppler Monitoring (“ODM”), this morning announced the addition of a major new hospital in the USA. The hospital is a
OptiBiotix Health plc (AIM:OPTI), a life sciences business developing compounds to tackle obesity,high cholesterol, diabetes and skin care, announced this morning that it has had an abstract accepted for presentation
Avacta Group Plc (LON:AVCT) is the proprietary owner of Affimer technology for the development of bio-therapeutics, diagnostic tests and research reagents. Affimers represent a radical alternative to established antibody technology
Evgen Pharma (LON:EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, this morning announced that the results of mechanistic studies into SFX-01, the
Advanced Oncotherapy (LON:AVO), the developer of next-generation proton therapy systems for cancer treatment, told DirectorsTalk that yesterday Dr Enrico Vanni, Non-Executive Director of the Company purchased 40,000 ordinary shares of
Cambridge Cognition Holdings PLC (LON:COG), the specialist developer of computerised tests for detection and monitoring of neuropsychological disorders, today announced a trading update for the year ending 31 December 2017.
© 2023 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
